Australia Health

CSL (ASX:CSL) announced that Dr. Paul McKenzie will retire as CEO and Managing Director, effective immediately.

Immuron (ASX:IMC) announced a leadership transition, following the resignation of Phillip Hains as CFO and company secretary.

Algorae Pharmaceuticals (ASX:1AI) has formalised a definitive license and supply agreement with India’s Cadila Pharmaceuticals.

Memphasys (ASX:MEM) has announced that its flagship Felix System has secured official approval from the Therapeutic Goods Administration.

Atomo Diagnostics (ASX:AT1) has secured a material purchase order worth approximately $630,000 from the National Association of People with HIV Australia for the supply of HIV self-tests.

Immutep (ASX:IMM) announced a significant operational breakthrough in its global TACTI-004 (KEYNOTE-F91) Phase 3 clinical trial.

Australian biotech firm Terragen (ASX:TGH) announced binding commitments for a $7 million equity raising.

Neuren Pharmaceuticals (ASX:NEU) has commenced dosing in its "Koala" Phase 3 clinical trial.

Healthscope's lenders are poised to endorse a rescue plan that will transform the nation's second-largest private hospital operator into a not-for-profit entity.

Epsilon Healthcare (ASX:EPN) partnered with Puro New Zealand in a multi-year deal to manufacture organic medicinal cannabis.

Neuren Pharmaceuticals (ASX:NEU) secures FDA feedback for NNZ-2591, validating its HIE study path and Pitt Hopkins trial endpoints for a 2026 launch.

Island Pharmaceuticals (ASX:ILA) secured $9 million in strategic funding, raised through a placement of approximately 25.7 million new ordinary shares priced at $0.35 each.